PD-L1 Targeting Peptide Probe for PET Imaging of Solid Tumor

Inclusion criteria

• Aged 18-75, male and female, with ECOG score of 0 or 1;
• Subjects with lung cancer, melanoma, or other solid tumors scheduled for immunotherapy or combined immunotherapy;
• underwent PD-L1 IHC examination before therapy;
• The expected survival was more than 26 weeks;
• Blood routine test, liver and kidney function meet the following standards: blood routine: WBC >= 4.0 x 10^9/L or neutrophil >= 1.5 x 10^9/:, PLT >= 100 x 10^9 / L, Hb >= 90g / L; Pt or APTT <= 1.5 upper limit of normal value; liver and kidney function: total bilirubin <= 1.5 x ULT (upper limit of normal value), ALT / AST <= 2.5 upper limit of normal value or <= 5 x ULT (subject with liver metastasis), ALP <= 2.5 upper limit of normal value (if bone metastasis or liver metastasis exists, ALP <= 4.5 upper limit of normal value); BUN <= 1.5 x ULT, SCR <= 1.5 x ULT;
• According to RECIST1.1, there was at least one measurable target lesion;
• Understand and sign informed consent voluntarily with good compliance.

Exclusion criteria

• The function of liver and kidney was seriously abnormal;
• Preparation for pregnant, pregnant and lactating women;
• Inability to lie flat for half an hour;
• Suffering from claustrophobia or other mental disorders;
• Other researchers considered it unsuitable to participate in the trial.